17:16 , Feb 22, 2019 |  BC Week In Review  |  Clinical News

Keytruda misses survival endpoints in Phase III HCC trial

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab missed the co-primary endpoints of improving overall survival (OS) and progression-free survival (PFS) in the Phase III KEYNOTE-240 trial to treat advanced hepatocellular carcinoma. Merck declined to...
22:41 , Feb 20, 2019 |  BC Extra  |  Clinical News

Keytruda misses survival endpoints in Phase III HCC trial

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab missed the co-primary endpoints of improving overall survival (OS) and progression-free survival (PFS) in the Phase III KEYNOTE-240 trial to treat advanced hepatocellular carcinoma. Merck declined to...
22:27 , Feb 8, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 6 profitable biotechs and pharmas are slated to report earnings this week. (A) Premarket on U.S. exchange; during trading hours in Tel Aviv; (B) Premarket on U.S. exchange; during trading...
22:53 , Jan 15, 2019 |  BC Week In Review  |  Clinical News

FDA approves Cabometyx for liver cancer

Exelixis Inc. (NASDAQ:EXEL) said Jan. 14 that FDA approved Cabometyx cabozantinib to treat hepatocellular carcinoma patients previously treated with Nexavar sorafenib. The approval comes two months after Exelixis’ partner Ipsen Group (Euronext:IPN; Pink:IPSEY) received approval...
00:30 , Jan 15, 2019 |  BC Extra  |  Company News

FDA approves Cabometyx for liver cancer

Exelixis Inc. (NASDAQ:EXEL) said Monday FDA approved Cabometyx cabozantinib to treat hepatocellular carcinoma patients previously treated with Nexavar sorafenib. The approval comes two months after Exelixis’ partner Ipsen Group (Euronext:IPN; Pink:IPSEY) received approval from the...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
19:06 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

MMRF launches MyDRUG multiple myeloma platform trial

The Multiple Myeloma Research Foundation launched the collaborative MyDRUG platform trial to identify new treatment options for molecularly defined subgroups of patients. The Phase I/II signal-finding study builds upon the patient group's 2011 CoMMpass trial,...
15:49 , Nov 29, 2018 |  BC Extra  |  Clinical News

MMRF launches MyDRUG multiple myeloma platform trial

The Multiple Myeloma Research Foundation launched the collaborative MyDRUG platform trial to identify new treatment options for molecularly defined subgroups of patients. The Phase I/II signal-finding study builds upon the patient group's 2011 CoMMpass trial,...
17:28 , Nov 9, 2018 |  BC Week In Review  |  Company News

Earnings roundup: Puma falls on Nerlynx sales miss; cabozantinib sales lift Exelixis

Puma Biotechnology Inc. (NASDAQ:PBYI) shares tumbled, while Exelixis Inc. (NASDAQ:EXEL) gained after the companies reported 3Q18 financial results for their flagship therapies. Puma lost $18.53 (48%) to $20.07 on Nov. 2 after the company said...